$2.10
-0.07-3.23%
At Close: -
$2.14
0.041.90%
After Hours: 7:21 AM EDT
15 minutes delayed
Comments
Loading...
Cellectis
CLLSNASDAQ
want to know what
the Bulls & Bears Say?
Cellectis (NASDAQ:CLLS) Stock, Analyst Ratings, Price Targets, Forecasts
Cellectis SA has a consensus price target of $9.5 based on the ratings of 7 analysts. The high is $16 issued by Citigroup on April 5, 2023. The low is $2 issued by Goldman Sachs on May 24, 2022. The 3 most-recent analyst ratings were released by Oppenheimer, JMP Securities, and JMP Securities on June 12, 2024, May 31, 2024, and November 1, 2023, respectively. With an average price target of $7.33 between Oppenheimer, JMP Securities, and JMP Securities, there's an implied 242.68% upside for Cellectis SA from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
JMP Securities
Citigroup
Goldman Sachs
Barclays
1calculated from analyst ratings
Analyst Ratings for Cellectis
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/12/2024 | Buy Now | 367.29% | Oppenheimer | Hartaj Singh | $11 → $10 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | 180.37% | JMP Securities | Silvan Tuerkcan | $6 → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/01/2023 | Buy Now | 180.37% | JMP Securities | Silvan Tuerkcan | $6 → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/08/2023 | Buy Now | 414.02% | Oppenheimer | Hartaj Singh | → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2023 | Buy Now | 180.37% | JMP Securities | Silvan Tuerkcan | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/05/2023 | Buy Now | 647.66% | Citigroup | Yigal Nochomovitz | $24 → $16 | Maintains | Buy | Get Alert |
| 03/13/2023 | Buy Now | 507.48% | Oppenheimer | Hartaj Singh | $16 → $13 | Maintains | Outperform | Get Alert |
| 03/13/2023 | Buy Now | 180.37% | JMP Securities | Silvan Tuerkcan | → $6 | Reiterates | → Market Outperform | Get Alert |
| 01/19/2023 | Buy Now | 180.37% | JMP Securities | Silvan Tuerkcan | $11 → $6 | Maintains | Market Outperform | Get Alert |
| 05/24/2022 | Buy Now | -6.54% | Goldman Sachs | Salveen Richter | $3 → $2 | Maintains | Sell | Get Alert |
| 05/18/2022 | Buy Now | — | Baird | Jack Allen | — | Upgrade | Neutral → Outperform | Get Alert |
| 05/13/2022 | Buy Now | 227.1% | Barclays | Gena Wang | $9 → $7 | Maintains | Overweight | Get Alert |
| 01/06/2022 | Buy Now | 647.66% | Wells Fargo | Nick Abbott | → $16 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/30/2021 | Buy Now | 834.58% | JMP Securities | Silvan Tuerkcan | — | Initiates | → Market Outperform | Get Alert |
| 10/08/2021 | Buy Now | 367.29% | Baird | Jack Allen | — | Downgrade | Outperform → Neutral | Get Alert |
FAQ
What is the target price for Cellectis (CLLS) stock?
The latest price target for Cellectis (NASDAQ:CLLS) was reported by Oppenheimer on June 12, 2024. The analyst firm set a price target for $10.00 expecting CLLS to rise to within 12 months (a possible 367.29% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cellectis (CLLS)?
The latest analyst rating for Cellectis (NASDAQ:CLLS) was provided by Oppenheimer, and Cellectis maintained their outperform rating.
When was the last upgrade for Cellectis (CLLS)?
The last upgrade for Cellectis SA happened on May 18, 2022 when Baird raised their price target to N/A. Baird previously had a neutral for Cellectis SA.
When was the last downgrade for Cellectis (CLLS)?
The last downgrade for Cellectis SA happened on January 6, 2022 when Wells Fargo changed their price target from N/A to $16 for Cellectis SA.
When is the next analyst rating going to be posted or updated for Cellectis (CLLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectis was filed on June 12, 2024 so you should expect the next rating to be made available sometime around June 12, 2025.
Is the Analyst Rating Cellectis (CLLS) correct?
While ratings are subjective and will change, the latest Cellectis (CLLS) rating was a maintained with a price target of $11.00 to $10.00. The current price Cellectis (CLLS) is trading at is $2.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.